regulatory
confidence high
sentiment negative
materiality 0.62
Alzamend pauses AL001 bipolar trial after FDA rejects enrollment-criteria change; MGH terminates BD SOW
Alzamend Neuro, Inc.
- FDA wrote on Oct 15, 2026 that the AL001 bipolar trial design did not appear adequate and well-controlled enough to support an NDA.
- Alzamend paused the BD Clinical Trial on Oct 21, 2026 after MGH said co-morbidity exclusions (diabetes, cardiovascular disease, anxiety) hampered enrollment.
- MGH terminated the bipolar statement of work on Nov 11, 2026 and will refund about $25,000 in unused funds; the Healthy SOW is unaffected.
- Company will seek a Type B FDA meeting on a revised plan expected to drop Phase II and move directly to a Phase III efficacy/safety trial in bipolar; feedback targeted by end of Q2 2027.
- Final clinical study report and results for the Healthy Patient Clinical Trial, initiated May 2025 and completed Nov 2025, are expected in December 2026.
Featured in Daily 8-K Digest
Selected #6 for 2026-11-17.
Read digest